Thorough QT (TQT) Study of TD-4208 in Healthy Subjects
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if TD-4208, an investigational drug being developed
to treat people with chronic obstructive pulmonary disease (COPD), has any effect on the
electrical activity of the heart.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Inc. Theravance Biopharma R & D, Inc.
Collaborator:
Theravance Biopharma
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination